Buy Olaparib 150 mg online, Buy Lynparza online

Olanib is the alternative & generic version of Lynparza by AstraZeneca. Olanib is manufactured by Everest Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.

Olanib (Lynparza) Olaparib by EverestPharma is used to treat cancers such as ovarian Cancer, Breast, Fallopian Tube, Pancreatic, Peritoneal Cancer, Prostate.

Indications:

Breast Cancer: Olaparib is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before Olaparib treatment is initiated.

Ovarian Cancer: Olaparib is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed (PSR) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinumbased chemotherapy.

Therapeutic Class

Targeted Cancer Therapy

Pharmacology

Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair.

Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy and following platinum-based chemotherapy.

Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA.

In vitro studies have shown that Lynparza-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

Dosage & Administration

There is a risk of medication errors between Olaparib tablets and Olaparib capsules. In order to minimize this risk, check the bottle labels to ensure that the drug being prepared and dispensed is Olaparib tablets and not Olaparib capsules.

The recommended total daily dose of Lynparza tablets is 600 mg, taken as two 150 mg tablets twice daily. The 100 mg tablet is available for dose reduction.

For treatment of ovarian cancer: Patients should start treatment with Olaparib no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have recovered from prior hematologic toxicities prior to starting Olaparib.

It is recommended that Lynparza treatment be continued until progression of the underlying disease or unacceptable toxicity. Olaparib should not be given in combination with other anti-cancer therapy.

Interaction

Clinical studies of olaparib in combination with other anti-cancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. The recommended Lynparza monotherapy dose is not suitable for combination with myelosuppressive anti-cancer agents.

Co-administered CYP3A inhibitors or inducers may respectively increase or decrease olaparib plasma concentration.

Contraindications

Olaparib is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation.

Side Effects

The most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). The following serious ADRs were reported in one patient each: dermatitis allergic, neutrophil count decreased, and platelet count decreased.

The proportion of patients who permanently discontinued Lynparza due to adverse events was 4.9% in the Olaparib arm compared with 7.7% in the chemotherapy arm.

Pregnancy & Lactation

Pregnancy: Olaparib can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. Lynparza wasteratogenic and caused embryo-fetal toxicity in rats at exposures below those in patients receiving the recommended human dose of 400 mg twice daily.

If this drug is used during pregnancy, or if a patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus and the potential risk for loss of the pregnancy.

Nursing Mothers: It is not known whether olaparib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Lynparza, a decision should be made.

Precautions & Warnings

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): occurred in patients exposed to Olaparib, and the majority of reports were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed.

Pneumonitis: occurred in patients exposed to Lynparza, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed.

Embryo-Fetal Toxicity: Olaparib can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

Use in Special Populations

Pediatric Use: The safety and efficacy of Lynparza has not been established in pediatric patients.

Overdose Effects

There is no specific treatment in the event of Lynparza overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should follow general supportive measures and should treat symptomatically.

Storage Conditions

Store in a dry place below 30°C, protect from light. Keep out of the reach of children.